Immunic to participate in scientific conferences in october

New york , oct. 4, 2023 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in october: october 11-13: msmilan2023: the 9th joint ectrims-actrims meeting. robert j. fox, md, staff neurologist, mellen center for multiple sclerosis, vice-chair for research, neurologic institute, cleveland clinic, cleveland, ohio, will present data from immunic's phase 2 emphasis trial of vidofludimus calcium (imu-838) in relapsing-remitting multiple sclerosis (ms), in an eposter at this meeting in milan, italy.
IMUX Ratings Summary
IMUX Quant Ranking